Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced that management will present at the ...
CRVS stock surged more than 200% in early 2026 as investors repriced its oral ITK inhibitor opportunity. Erasca Inc (ERAS) secured $258.8 million in fresh capital and holds patent protection on ...
This review examines how zinc regulates inflammatory and redox signaling pathways involved in myocarditis and pericarditis, highlighting mechanisms such as NF-κB inhibition and the redox zinc switch.
Salicornia, which is colloquially known as ‘sea asparagus,’ is rapidly emerging as a transformative solution for future food ...
Pasithea Therapeutics Corp. ( KTTA) Oppenheimer 36th Annual Healthcare Life Sciences Conference February 26, 2026 4:00 PM EST ...
The issued patent provides intellectual property protection for ERAS-4001 and related compositions until at least 2043 Expands Erasca's diversified IP portfolio for RAS-driven cancers Initial Phase 1 ...
The issued patent provides intellectual property protection for ERAS-4001 and related compositions until at least 2043 Expands Erasca’s diversified IP portfolio for RAS-driven cancers Initial Phase 1 ...
Phase 1b translational data demonstrate localized ileocolonic target engagement, suppression of inflammatory and fibrotic gene programs, and ...
When 200 natural accessions of the model plant Arabidopsis thaliana grown in a nitrate-enriched medium were compared, one observation stood out: some accessions formed significantly longer lateral ...
On February 4, 2026, Verastem Oncology reported preliminary, unaudited 2025 financial and clinical results, highlighting an estimated $17.5 million in fourth-quarter 2025 net product revenue and $30.9 ...
A new human study has uncovered how the body naturally turns off inflammation. Researchers found that fat-derived molecules called epoxy-oxylipins rein in immune cells that can otherwise drive chronic ...
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results